RxDoctor Payments Data

Laura Mason, MD

Neurology · Hendersonville, NCNPI 1831392828

Payments from drug & device makers

$8,729in general payments, 2019–2025

Across 600 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$1K
  • MDD US Operations, LLC$673
  • Novartis$594
  • Biogen$486
  • Supernus Pharmaceuticals, Inc.$420
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$8,55898%
  • Education$1712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,729 in reported general payments places this provider in the 70th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$68,038
Medicare patients
469
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab23$215,026
UbrelvyUbrogepant50$83,557
Aimovig AutoinjectorErenumab-Aooe74$66,403
Nurtec OdtRimegepant Sulfate34$55,813
QuliptaAtogepant37$43,661
Lamictal XrLamotrigine22$33,311
BotoxOnabotulinumtoxina23$29,943
VimpatLacosamide13$15,908
ZavzpretZavegepant Hcl14$14,348
Teriflunomide35$14,078
Emgality PenGalcanezumab-Gnlm15$12,876
FingolimodFingolimod Hcl27$8,023
Lacosamide58$5,129
MovantikNaloxegol Oxalate12$4,909
Carbidopa-LevodopaCarbidopa/Levodopa274$4,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$1,175$157,162110 claims
PfizerNurtec Odt, Zavzpret, Dilantin$206$70,78559 claims
UCB, Inc.Vimpat$90$15,90813 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$219$2,10342 claims
Upsher-smith Laboratories LLCTopiramate$27$1,008162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 566 neurology providers in North Carolina.

Other neurology in Hendersonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →